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We recently showed that losartan and paricalcitol are
synergistic in the treatment of diabetic nephropathy in a
model of type 1 diabetes. To test this strategy in a model of
type 2 diabetes, we treated 2-month-old diabetic Lprdb/db
mice with losartan, paricalcitol, or a combination of losartan
and paricalcitol for 3 months. Vehicle-treated diabetic mice
developed progressive albuminuria and glomerular
abnormalities with mesangial expansion and
glomerulosclerosis compared to their non-diabetic littermate
control mice. Accompanying damage of the glomerular
filtration barrier was a marked reduction in podocyte number
as well as reduced expression of slit diaphragm proteins.
Further, there was increased glomerular expression of
extracellular matrix proteins, monocyte chemoattractant
protein-1 and transforming growth factor-b. Losartan or
paricalcitol each alone moderately ameliorated albuminuria
and glomerular damage. However, their combined use
showed a dramatic therapeutic synergism, manifested by
prevention of progressive albuminuria, restoration of the
glomerular filtration barrier, reversal of the decline in slit
diaphragm proteins, reduced synthesis of extracellular matrix
proteins, and reduction of glomerulosclerosis. These effects
were accompanied by blockade of the compensatory
increase of renin production and angiotensin I/II
accumulation in the kidney. Thus, our study further shows
that vitamin D analogs can increase the efficacy of AT1
receptor blockade, leading to a more effective prevention of
kidney disease in type 2 diabetes.
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Type 2 diabetes mellitus is an increasingly prevalent disease
around the globe. Diabetic nephropathy is the most common
renal complication of diabetes mellitus and a leading cause of
end-stage renal disease. Hyperglycemia is the main determi-
nant for diabetic nephropathy, which promotes glomerular
injury through multiple pathways, including stimulation of
profibrotic and proinflammatory factors and increase of
oxidative stress. A large body of evidence has shown that
the main mediator of hyperglycemia-induced renal damage is
the activation of the local renin–angiotensin system (RAS) in
the kidney. Intrarenal renin and angiotensinogen levels are
induced in diabetic animals.1,2 High glucose has been shown
to induce renin and angiotensin (Ang) II production in
mesangial cell and podocyte cultures.3–5 Accumulation of
Ang II in diabetic kidneys causes renal injury by promoting
glomerular oxidative and inflammatory stress, increasing
glomerular fibrosis, and damaging the glomerular filtration
barrier. Given the critical role of the RAS in diabetic renal
damage, inhibition of the RAS is presently the first-line
therapeutic strategy for the treatment of diabetic nephro-
pathy in humans. Drugs that target the RAS, including ACE
inhibitors, AT1 blockers, and renin inhibitors, have been
shown in clinical studies to reduce the progression of
glomerulosclerosis, tubulointerstitial fibrosis, and proteinuria
in humans.6–11 Because of the disruption of the negative
feedback inhibitory loop in renin production, however, a
problem for the RAS-inhibiting drugs is the appearance of
compensatory renin increase that eventually increases Ang II
production and reduces the efficacy of RAS inhibition.12
Renin increase can also activate the (pro)renin receptor13
and cause renal and cardiovascular damages independent of
Ang II.14
Recently, we reported a therapeutic strategy with combi-
nation of vitamin D analog paricalcitol (P) (19-nor-1,25-
dihydroxyvitamin D2) and AT1 blocker losartan (L) that
generated excellent therapeutic synergism in blocking the
development of diabetic nephropathy in a type 1 diabetes
model.15 The molecular basis for the therapeutic synergism is
the blockade of the compensatory renin increase by P, leading
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to reduced Ang I/II accumulation in the kidney. This is
because the hormonal form of vitamin D, 1,25-dihydrox-
yvitamin D (1,25(OH)2D3), has been well established as a
negative endocrine regulator of the RAS,16 and 1,25(OH)2D3
and its analogs suppress renin gene transcription as well as
high glucose-induced angiotensinogen (AGT) produc-
tion.17–20 This combination strategy provides a novel and
effective therapeutic method for the treatment of diabetic
nephropathy, and thus has important clinical implications.
However, whether this strategy is therapeutically effective in
type 2 diabetes models has not been studied. Given
that type 2 diabetes is much more prevalent in humans
than type 1 diabetes, it is important to test this strategy in
type 2 diabetes models. Here, we report the investigative
results using db/db mice, a commonly used type 2 diabetes
model.
RESULTS
It is known that db/db mice in C57BL/6-KS background
develop detectable diabetic nephropathy;21 thus we chose this
model to test the therapeutic efficacy of the L and P
combination. Two-month-old male db/db mice were rando-
mized into four groups (n¼ 6–7 in each group) and treated
respectively with vehicle (V), L, P, or Lþ P combination for
3 months, with non-obese db/þ mice as the non-diabetic
control. As shown in Figure 1, blood glucose levels in all
db/db mouse groups gradually increased to 600mg/dl over
the 3-month period, and all drug treatments had no effects
on the blood glucose levels in these mice (Figure 1a). The
drug treatments also had little effects on the body weight gain
in all db/db mice (Figure 1b). As expected, the baseline
urinary albumin levels in db/db mice at 2 months of age
(month 0) was much higher than that of db/þ mice, and age
had little effect on the urinary albumin level in db/þ mice
(Figure 1c). In contrast, db/db mice treated with V showed a
gradual increase in urinary albumin levels with aging, and
the urinary albumin to creatinine ratio increased by
about twofold in this 3-month period (Figure 1c). L and P
mono-treatment was able to moderately slow down the
development of albuminuria; however, Lþ P co-treatment
completely prevented the progressive increase of albumin to
creatinine ratio in db/db mice (Figure 1c). These treatments
db/+ V L P L+P
db/+ V L P L+P
db/+ V L P L+Pdb/+ V L P L+P
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0
*
*
*
Month
700
800
900
600
500
400
300
200
100
0
700
600
500
400
300
200
100
0
AC
R 
(μ
g/
m
g)
Se
ru
m
 c
re
at
in
in
e 
(m
g/d
l)
BU
N 
(m
g/d
l)
16
14
12
10
8
6
4
2
0
0
20
40
60
100
120
80
Ki
dn
ey
/b
od
y 
we
ig
ht
 (m
g/g
)
70
60
50
40
30
20
10
0
*
#
**
*
*
*
*
*
*#*#*#
0 1 2 3
0 1 2 3
Bo
dy
 w
ei
gh
t (g
)
Bl
oo
d 
gl
uc
os
e 
(m
g/d
l)
Figure 1 | Effect of drug treatments on blood glucose, body weight, kidney mass, and serum and urinary parameters. Two-month-
old male db/db mice were treated with vehicle (V), losartan (L, 0.05mg/ml), paricalcitol (P, 0.4 mg/kg), or a combination of losartan and
paricalcitol (Lþ P) for 3 months. db/þ mice are non-diabetic control without any drug treatment. (a) Blood glucose levels; (b) body weight
curves; (c) changes in urinary albumin to creatinine ratio (ACR) over the time; *Po0.017 vs V; #Po0.017 vs L or P. Two-way analysis of
variance interaction term, Po0.001 at 3 month; n¼ 6–7. (d) Kidney mass to body weight ratio at the end of treatment. Note the kidney to
body weight ratio is much higher in db/þ mice because their body weight is much less than that of db/db mice; (e) serum creatinine levels;
(f) blood urea nitrogen (BUN) levels. *Po0.017 vs V; #Po0.017 vs L, n¼ 6–7.
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also reduced renal hypertrophy associated with chronic
hyperglycemia, with Lþ P combination having the most
dramatic effect on the kidney mass to body weight ratio in
db/db mice (Figure 1d). Moreover, V-treated db/db mice
showed significantly increased serum creatinine and blood
urea nitrogen levels (Figure 1e and f), and Lþ P combination
showed significant reduction in blood urea nitrogen levels
(Figure 1f), consistent with improved kidney functions.
To correlate the reduction of albuminuria to glomerular
structure, we examined the glomerular filtration barrier by
electron microscopy. As shown in Figure 2, db/þ mice
showed normal morphology in the endothelial cells, GBM,
and podocyte foot processes. In V-treated db/db mice, a
marked increase in GBM thickness and foot process
effacement were seen (Figure 2a), consistent with the severe
albuminuria seen in these mice. Treatment with L or P alone,
particularly with Lþ P, blocked the thickening of the GBM
and foot process effacement, which basically normalized the
glomerular filtration barrier structure (Figure 2a). Quantifi-
cation of the GBM thickness in each treatment group
confirmed these observations (Figure 2b).
Podocytes have a key role in maintaining the integrity of
the glomerular filtration barrier, and diabetic renal injury is
known to lead to loss of podocytes.22 We surveyed podocytes
in glomeruli by immunostaining with anti-WT1 antibody,
a podocyte-specific antibody. As shown in Figure 3, there was
a marked reduction in glomerular WT1-positive cells in
V-treated db/db mice relative to db/þ mice, and all of the
drug treatments, particularly Lþ P, effectively prevented the
decline of WT1-positive cell number in db/db mice (Figure
3a and b).
The slit diaphragm is the key structure that controls
protein filtration through the glomerular filtration barrier.23
As shown in Figure 4, relative to the db/þ controls, the
mRNA levels of nephrin, a-actinin-4, CD2AP, Neph-1, and
FAT-1 were significantly reduced in V-treated db/db mice,
and treatment with P and Lþ P prevented the reduction of
these proteins to different extents, with Lþ P showing the
best results (Figure 4a). Further quantification of the reverse
transcription (RT)-PCR data confirmed these findings
(Figure 4b). Together, these data indicate that the magnitude
of albuminuric reduction correlates with the normalization
of podocyte number and key slit diaphragm proteins in the
kidney.
The effect of drug treatments on glomerular sclerosis was
assessed by periodic acid-Schiff staining. Compared with
db/þ mice, V-treated db/db mice showed a clear glomerular
mesangial expansion and some degrees of glomerulosclerosis,
with increased accumulation of extracellular matrix in the
mesangium (Figure 5a–c). L or P mono-treatment moder-
ately reduced the degree of glomerular sclerosis, but Lþ P
had much better effects on the reduction of mesangial
sclerosis and expansion, as was confirmed by semiquantita-
tive assessments of the kidney sections (Figure 5b and c).
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Figure 2 | Structure of glomerular filtration barrier. (a) Kidney samples from non-diabetic db/þ control mice and db/db mice
treated with V, L, P, and Lþ P were subject to electron microscopic analyses. Shown is the structure of the glomerular filtration barrier,
including endothelial cells, glomerular basement membrane (GBM), and podocyte foot process. Arrow pairs point to both sides of the
GBM. Asterisks indicate area of foot process effacement in V-treated db/db mice. Note the marked thickening of the GBM from V-treated
db/db mice. (b) Quantification of GBM thickness in these groups of mice. *Po0.017 vs V; #Po0.017 vs L. Two-way analysis of variance
interaction term, P¼ 0.0013.
1002 Kidney International (2010) 77, 1000–1009
or ig ina l a r t i c l e DK Deb et al.: Treatment of diabetic nephropathy in type 2 diabetes
We then determined the levels of monocyte chemoattrac-
tant protein-1 (MCP-1), transforming growth factor-b, and
fibronectin (FN) and collagen IV, two major extracellular
matrix proteins that contribute to glomerular sclerosis.
RT-PCR showed that, compared with db/þ controls,
V-treated db/db mice had a marked increase in MCP-1,
transforming growth factor-b, FN, and collagen IVexpression
at mRNA levels (Figure 6a and b). Immunostaining using
FN-specific antibody showed strong expression of FN in
the mesangium of V-treated db/db mice (Figure 6c). The
drug treatments, particularly Lþ P combination, effectively
decreased the induction of MCP-1, transforming growth
factor-b, FN, and collagen IV in db/db mice (Figure 6a and
b), and immunostaining confirmed the reduction of FN in
the glomerulus (Figure 6c).
Intrarenal RAS activation has a key role in hyperglycemia-
induced renal injury. Indeed, relative to db/þ mice,
V-treated db/db mice showed a marked elevation in
renin and angiotensinogen (AGT) expression in the kidney
(Figure 7a and b), and immunostaining showed strong renin
expression in the juxtaglomerular cells of V-treated db/db
mice (Figure 7c). As expected, L mono-treatment led to even
more elevation of renin expression (Figure 7a and b), as a
result of a compensatory induction. Immunostaining showed
that renin induction in L-treated kidneys not only occurred
in the juxtaglomerular cells (Figure 7c, single arrows), but
also in other glomerular cells (Figure 7c, double arrows).
Consequently, Ang I/II levels were also markedly increased in
the kidney cortex (both glomerular and tubular areas) of
L-treated mice, shown by immunostaining with Ang I/II-
specific antibodies (Figure 7d). As expected, P-treatment
reduced renin as well as AGT17 (relative to V-treated db/db
mice), and Lþ P co-treatment suppressed the induction of
renin and AGT expression (Figure 7a and b), which should
lead to a decrease in Ang I/II production. Immunostaining
confirmed that renin and Ang I/II was clearly reduced in the
Lþ P-treated kidney sections (Figure 7c and d). This is
consistent with the prediction that P can block the reactive
increase of renin and Ang I/II, leading to better therapeutic
effects.
Activation of nuclear factor-kB contributes to hypergly-
cemia-induced renal damage. We assessed the effect of the
treatments on glomerular nuclear factor-kB activation by
measuring p65 nuclear translocation using immunostaining.
As shown in Figure 8, p65-positive glomerular nuclei were
increased in V-treated mice, and P treatment, but not
L treatment, reduced the number of p65-positive cells. Thus,
Lþ P did not show more inhibition than P (Figure 8).
Finally, we addressed the effect of the treatments on the
systemic metabolism and inflammation by measuring plasma
lipid levels and adipose inflammatory cytokines. Compared
with db/þ mice, V-treated db/db mice showed elevated
plasma triglyceride and total cholesterol levels, as expected.
L, P, and Lþ P treatment reduced triglyceride but not
cholesterol levels (Figure 9a). In the adipose tissue, tumor
necrosis factor-a, interleukin-6, and MCP-1 were markedly
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Figure 3 |Changes in the number of glomerular podocytes. (a) Immunostaining of kidney slides with anti-WT1-antibody. Shown are
representatives of a single glomerulus from each group of mice as indicated. (b) Average WT1-positive podocytes per glomerulus.
Glomeruli (30/mouse) were randomly selected for counting from the sections in each group of mice. *Po0.017 vs V; #P¼ 0.054 vs L.
Two-way analysis of variance interaction term, P¼ 0.057.
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elevated in V-treated db/db mice, and interleukin-6 and
MCP-1 expression was reduced to the same degree by P or
Lþ P treatment (Figure 9b and c). L treatment had no effects
on these adipose cytokines (data not shown).
DISCUSSION
This work is an extension of a previous study that
demonstrated excellent efficacy of AT1 blocker and vitamin
D analog combination therapy in the prevention of renal
injury in diabetic mice.15 This combination therapy is based
on the principle that vitamin D analogs suppress the
compensatory increase of renin production caused by
inhibitors of the RAS, resulting in better therapeutic efficacy.
Our previous study has shown that L and P combination
produced therapeutic synergism in a type 1 diabetes model.15
Here, we demonstrate that this therapeutic strategy also
works in type 2 diabetes models. This study has important
clinical implications, as type 2 diabetes is highly prevalent in
humans and is by far the main cause of chronic kidney
disease and resultant high mortality across different racial
populations.
The db/db mouse model is a widely used type 2 diabetes
model that develops diabetic nephropathy with age,
as evident by age-dependent appearance of progressive
albuminuria and glomerular damages.21 Because of the lack
of a functional leptin receptor, db/db mice are extremely
obese due to hyperphagia. These mice are also known to have
elevated circulating 1,25(OH)2D3 levels.
24,25 These two
characteristics cast doubt on the effectiveness of vitamin D
therapy in this model, because, as fat-soluble molecules,
vitamin D analogs may be trapped in the excessive adipose
tissue leading to low efficacy, and the high circulating
1,25(OH)2D3 may have already chronically desensitized the
mice to vitamin D actions. Our data demonstrated that even
in this extremely obese and hypervitaminosis D model
vitamin D therapy was still effective. Given that a large
portion of type 2 diabetes patients is obese, this finding has
important clinical implications. However, probably for the
above reasons, we did notice that the suppression of renin
expression in db/db mice appeared to be less dramatic
compared with what we observed previously in the non-
obese type 1 diabetes model at similar vitamin D doses.15,26
Therefore, it is possible that higher doses may achieve better
renin suppression and thus better therapeutic effects in obese
models.
In this study, we treated db/db mice with L (an AT1
blocker), P (an activated vitamin D analog), or their
combination for 3 months. These long-term treatments had
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little impact on growth or on the hyperglycemic status of
db/db mice, suggesting that the treatments directly targeted
the kidney rather than glucose metabolism. Our data showed
that both L and P had clear therapeutic effects on the
development of diabetic renal injury, as both inhibit the RAS;
however, it is the L and P combination that overall generated
db/+ V L P L+P db/+ V L P L+P
db/+ V L P L+P
MCP-1
FN
Col IV
GAPDH
TGF-β
R
el
at
iv
e 
m
R
N
A 
le
ve
ls
*
* #
*
* * *
*
*
*
6
5
4
3
2
1
0
FNMCP-1 Col IVTGF-β
Figure 6 | Expression of MCP-1, TGF-b, fibronectin, and collagen IV. (a) RT-PCR determination of fibronectin (FN) and collagen IV (Col IV)
mRNA expression in the kidney of all treatment groups as indicated. (b) Densitometric quantification of TGF-b, FN, and Col IV mRNA levels
based on the RT-PCR data. (c) Glomerular immunostaining for FN. Kidney sections from db/þ mice and db/db mice with different
treatments were immunostained with anti-FN antibody. *Po0.017 vs V; #Po0.017 vs L.
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Figure 5 | Effect of drug treatments on glomerulosclerosis. (a) Kidney sections were stained with periodic acid-Schiff (PAS).
Representative glomerular morphology of db/þ mice and db/db mice treated with V, L, P, and Lþ P as indicated. Note the expansion of
glomerular size in db/db mice. (b) Semiquantitative glomerulosclerotic score for the five groups of mice as indicated. *Po0.017 vs V;
#Po0.017 vs L or P. Two-way analysis of variance (ANOVA) interaction term, P¼ 0.0005. (c) Semiquantitative mesangial area in these mice
measured using computer software Image J (NIH, Bethesda, MD, USA). Thirty glomeruli were randomly selected for the quantitative
analyses. *Po0.017 vs V; #Po0.017 vs L. Two-way ANOVA interaction term, P¼ 0.24.
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better therapeutic effects than the mono-treatment. This is
manifested by complete blockade of the progression of
albuminuria and marked reduction of glomerular sclerosis in
db/db mice, two main pathological hallmarks of diabetic
kidney disease. At least part of the molecular basis for the
therapeutic synergism is the blockade of the compensatory
increase of renin expression by P, resulting in reduction of
Ang I/II accumulation in the kidney.
The complete blockade of albuminuria progression by the
co-treatment was accompanied by clear improvement of the
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Figure 7 | The status of the RAS in the kidney. (a) RT-PCR analysis of renin and angiotensinogen (AGT) expression in kidneys from the
five groups of mice as indicated. (b) Quantification of these gene transcripts based on the RT-PCR data. *Po0.017 vs V; #Po0.017 vs L
or P, n¼ 4. (c and d) Renin and Ang I/II levels in the kidney cortex. Kidney sections from the five groups of mice as indicated were
immunostained with renin-specific antibody (c) or AngI/II-specific antibody (d). Single arrows indicate juxtaglomerular cells, and double
arrows indicate other glomerular cells. Note the marked increase in renin and AngI/II levels in L-treated kidneys.
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glomerular filtration barrier structure. This includes preven-
tion of GBM thickening and reduction of podocyte
effacement and podocyte loss. Hyperglycemia-induced
GBM thickening and podocyte injury are known to lead to
albuminuria.27 At the molecular level, the combination
prevented the decline of slit diaphragm protein expression.
As these proteins are involved in the formation of the slit
diaphragm, disturbance of their expression results in
proteinuric nephropathy. Prevention of albuminiuria is of
particular clinical relevance, as microalbuminuria is a major
risk factor for progressive renal function decline in diabetic
nephropathy,28 which is thought to be the first step in an
inevitable progression to proteinuria and renal failure.29,30 In
fact, P has been reported to exhibit anti-proteinuric activity
in patients with chronic kidney disease, and the beneficial
effect was seen even in subjects already treated with ACEI or
ARB, indicating that the effect of P is additive to those of
ACEI/ARB in reducing proteinuria.31 The anti-proteinuric
property of P was further confirmed in a recent randomized
double-blinded pilot trial in patients with stage 2–3 chronic
kidney disease.32
Compared with humans, mice are notoriously resistant to
hyperglycemia-induced renal damage, particularly the
development of glomerulosclerosis and tubulointerstial
fibrosis. This may be partly due to the short lifespan of
rodents. Although the glomerular sclerosis seen in db/db
mice is moderate, the inhibitory effect of the drug treatments
was evident. The most effective antisclerotic effect was
seen in Lþ P treatment, which also showed the most
inhibition on the production of FN in the glomeruli. The
nuclear factor-kB pathway, which is known to have a role in
glomerular injury,33 is markedly suppressed by P and
the combination, and transforming growth factor-b, a well-
known profibrotic cytokine, was also targeted by these
treatments.
We presented evidence demonstrating that the basis for
the synergistic effect of L and P combination is the blockade
of RAS activation within the kidney, particularly the
elimination of the effect from compensatory renin induction.
The net consequence is the decrease of intrarenal
accumulation of Ang I/II, which is known to cause renal
damages through multiple pathways, including induction of
proinflammatory cytokines and profibrotic factors and
stimulation of oxidative stress in the kidney.34 Recent data
from a number of animal disease models and clinical studies
suggest that the intrarenal RAS is a main target of vitamin D
and its analogs against renal damage,35 and this study
provides more evidence to support this conclusion. However,
as a pleiotropic hormone, 1,25(OH)2D3 and its analogs may
also directly or indirectly influence other physiological and
pathological processes and pathways that contribute to their
effects on diabetic renal injury. For example, the effect of P
and the combination on systemic metabolism or adipose
inflammatory status may also contribute to their effects on
the kidney. Finally, the data presented here from a type 2
diabetes animal model also lend support for clinical trials
that measure therapeutic effects of vitamin D analogs in
patients with chronic kidney disease, as most of these patients
are with type 2 diabetes.
MATERIALS AND METHODS
Animals and treatment
Lprdb/db (db/db) and Lprdb/þ (db/þ ) mice in C57BL/6-KS
background were purchased from the Jackson Laboratories (Bar
Harbor, ME, USA). Two-month-old male db/db mice were
randomized into four groups and treated respectively with 80%
propylene glycol vehicle (intraperitoneal injection, 3 per week),
L (dissolved in drinking water at 0.05mg/ml, at approximately
3mg/kg/day), P at 0.4 mg/kg (dissolved in propylene glycol/
H2O¼ 80:20, intraperitoneal injection, 3 per week), or combination
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Figure 8 | Effects of the treatments on nuclear factor-jB activation in the glomerulus. Kidney sections from the five groups of mice
as indicated were stained with anti-p65 antibody (red) and nuclei were stained with DAPI (blue). The percentage of p65-positive nuclei
in the glomeruli was obtained by counting 430 glomeruli in each mice. *Po0.017 vs V; #Po0.017 vs L.
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of L and P for 3 months. The db/þ mice served as the non-diabetic
control. Spot urine collection, body weight, and fasting blood
glucose monitoring were performed monthly. All mice were killed 3
months after the first treatment started (at 5 months of age) and the
kidneys and abdominal fat pads were immediately harvested for
protein or RNA extraction or for histological analyses. The animal
study protocols were approved by the Institutional Animal Care and
Use Committee at The University of Chicago.
Serum and urine chemistry
Blood glucose levels were monitored with CONTOUR blood glucose
monitoring system (Bay Healthcare, Mishawaka, IN, USA). Serum
levels of creatinine and blood urea nitrogen were measured using
assay kits purchased from BioAssay Systems (Hayward, CA, USA).
Plasma triglyceride and total cholesterol levels were determined as
described previously.36 Urinary albumin and creatinine levels were
determined using commercial kits as reported previously.37
RT-PCR and quantitative RT-PCR
Total cellular RNAs were isolated using TRIzol reagents (Invitrogen,
Carlsbad, CA, USA). First-strand cDNAs were synthesized from 5 mg
of total RNAs in 20 ml reaction using MML-V reverse transcriptase
(Invitrogen) and hexanucleotide random primers. The first strand
cDNAs served as the template for PCR performed using Bioline
reagents (Bioline, Taunton, MA, USA) in a BioRad DNA Engine
(BioRad, Hercules, CA, USA), or for quantitative PCR performed in
Applied Biosystems 7900 Real Time PCR System using a SYBR green
PCR reagent kit (Applied Biosystems, Foster City, CA, USA) as
described previously.37 Glyceraldehyde-3-phosphate dehydrogenase
served as the internal controls. The PCR primers used in this study
were as described previously.15
Histology and immunohistochemistry
Freshly dissected kidneys were fixed overnight with 4% formalde-
hyde in phosphate-buffered saline (pH 7.2), processed, embedded in
paraffin, and cut into 3-mm sections. Renal sections were stained
with hematoxylin and eosin or with PAS. Semiquantitative scoring
of glomerular sclerosis in PAS-stained slides was performed by a
renal pathologist (AC) using a five-grade method described
previously:37,38 0, normal glomerulus; 1, sclerosis o25% of
glomerular surface; 2, sclerosis between 25 and 50%; 3, sclerosis
between 50 and 75%; and 4, sclerosis 475% of glomerular surface.
For immunostaining, kidney paraffin sections were first boiled in
10mM Na citrate solution (pH 6.0) for 10min to retrieve the
antigens. The sections were incubated with anti-fibronectin (Sigma,
St Louis, MO, USA), anti-renin (E-17), anti-WT1 (C-19), or anti-
Ang I/II (Santa Cruz Biotechnology, Santa Cruz, CA, USA)
antibodies, followed by incubation with horseradish peroxidase-
conjugated or Cy3-conjugated second antibody and the antigen was
visualized with a peroxidase substrate diaminobenzidine kit (Vector
Laboratories, Burlingame, CA, USA) or with a fluorescence
microscope.
Electron microscopy
Kidney tissue was fixed in 2% glutaraldehyde and then post-fixed in
1% osmium tetroxide in 0.1 M cacodylate buffer, pH 7.4 for 2 h at
room temperature. Electron microscopic analyses and quantification
of GBM were performed as described previously.37
Statistical analysis
Results are expressed as mean value±s.d. Pairwise comparisons of
L, P, and the combination of L and P with the vehicle-treated
group were carried out with the use of a two-sample t-test with an a-
value of 0.017 for each comparison (overall a-value, 0.05). A side
comparison between db/þ and vehicle-treated group were
carried out also using an a-value of 0.017. Two-factor analysis of
variance with interaction term and Dunnett’s t-test on comparisons
of L or P alone with the combination group were used to determine
whether the combination group had better effect than L alone or P
alone. The critical level for this analysis was 0.05. All statistical tests
were two-sided. All analyses were performed using SAS, mainly
PROC TTEST and PROC GLM (version 9.2, SAS Institute, Cary,
NC, USA).
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